Investor optimism following second-quarter financial results for fiscal year 2026–27 has driven significant multi-month gains across Indian CDMO equities. Major brokerages such as Motilal Oswal and ICICI Securities have aligned with this positive sentiment by assigning buy ratings and elevated price targets. For instance, Divi’s Laboratories climbed over 72% across six months, with its closing level of ₹11,450 exceeding the earlier November target projected by MOFSL.
Key points
Positive sentiment surrounding second-quarter fiscal 2026–27 results has driven a widespr…: Positive sentiment surrounding second-quarter fiscal 2026–27 results has driven a widespread rally among Indian pharmaceutical CDMO stocks.
Brokerages maintain room for further price appreciation across most tracked manufacturing…: Brokerages maintain room for further price appreciation across most tracked manufacturing firms relative to their recent trading closes.
Piramal Pharma captured a 38.65% six-month gain while remaining below its projected ₹270…: Piramal Pharma captured a 38.65% six-month gain while remaining below its projected ₹270 price target from Motilal Oswal Financial Services.
Sources checked by our analysis pipeline: 1
Pharma stocks have emerged as the star performers of Dalal Street over the past few months, especially the companies in the Contract Development and Manufacturing Organisation (CDMO) space. Laurus Labs, Gland Pharma, Piramal Pharma, and Divi’s Laboratories are some of the key pharma stocks in the space which have delivered up to 90% return over the past six months.
Most of these pharma stocks have continued to rally over the past few days amid optimism around their second quarter results for the financial year 2026-27. So let’s take a look at the spectacular six-month return by Laurus Labs, Gland Pharma, Piramal Pharma and Divi’s Laboratories and their target prices.
Laurus Labs target price
Laurus Labs has emerged as the outstanding performer in the CDMO space with its spectacular 88.64% rally over the past six months. The pharma stock closed at ₹2395.10 per share on BSE on Thursday. Motilal Oswal gave a target price of ₹2,830 per share for the stock.
Gland Pharma target price
Gland Pharma shares have rallied nearly 80.36% over the past six months. The stock closed at…
Belgian stocks ended higher at the close of trade, reflecting modest overall market gains. The benchmark BEL 20 index rose by 0.24% by the end of the trading session.
Trading concluded in negative territory as the regional market experienced a mild downward shift by the closing bell. Equity performance lost upward momentum, pulling the primary index into a minor deficit at the end of the trading session. Market participants saw mixed sentiment materialize into nominal losses across Swedish shares.
Equity markets in Finland completed their latest trading session in positive territory. The modest upward movement concluded the day's market activities with overall gains across Finnish shares. Investors saw local equities finish with positive momentum as trading drew to a close.